Who backs Candid Therapeutics?
21 investors| Investor | Type |
|---|---|
| Fidelity Management & Research Company | Asset manager |
| Qiming Venture Partners | Venture capital |
| OrbiMed | Growth equity |
| Franklin Resources | — |
| Venrock | Venture capital |
| Foresite Capital | Venture capital |
| Samsara BioCapital | Venture capital |
| Redmile Group | PE / buyout |
| venBio | Venture capital |
| Soleus Capital | PE / buyout |
| + 11 more investors · a free account shows the complete list | |
The directory is free. Investor activity — the working column — is Pro.Unlock prospecting columns
Membership and data by Private Market View
Candid Therapeutics investors
21 investors are on record for Candid Therapeutics, including Fidelity Management & Research Company, Qiming Venture Partners, OrbiMed and Franklin Resources. By type, the record holds 6 venture capital firms, 2 private equity firms and 1 asset manager. The Series B in Aug 2024 drew 20 investors.
Free account
More of Candid Therapeutics with a free account
- ·The complete investor list: 21 names
- ·Watch Candid Therapeutics: the Monday email on marks, rounds and moves
For fundraisers
Work this list, don’t just read it
These 21 firms already write checks for companies like Candid Therapeutics in drug discovery. Build the wider list: every firm that has backed a company like this one, ranked by how often and how recently.
Membership and data by Private Market View